Maria Jesus Jimenez Exposito

Nivolumab plus ipilimumab versus lenvatinib or sorafenib as first-line treatment for unresectable hepatocellular carcinoma (CheckMate 9DW): an open-label, randomised, phase 3 trial

Thomas Yau, Peter R. Galle, Thomas Decaens et al. · The Lancet · 2025 · 144 citations · Full text

CA209-9DX: phase III, randomized, double-blind study of adjuvant nivolumab vs placebo for patients with hepatocellular carcinoma (HCC) at high risk of recurrence after curative resection or ablation

Maria Jesus Jimenez Exposito, Mehmet Akce, José Luís Montero Álvarez et al. · Annals of Oncology · 2018 · 20 citations · Full text

Abstract No. 526 CheckMate-9DX: phase 3, randomized, double-blind study of adjuvant nivolumab vs placebo for patients with hepatocellular carcinoma (HCC) at high risk of recurrence after curative resection or ablation

Maria Jesus Jimenez Exposito, Mehmet Akce, J. Alvarez et al. · Journal of Vascular and Interventional Radiology · 2019 · 18 citations · Full text

Surgical Oncology, Abstract No, Hepatology +11

CA209-9DX: Phase III, randomized, double-blind study of adjuvant nivolumab vs placebo for patients with hepatocellular carcinoma (HCC) at high risk of recurrence after curative resection or ablation

Maria Jesus Jimenez Exposito, Mehmet Akce, José Luís Montero Álvarez et al. · Annals of Oncology · 2018 · 17 citations

Surgical Oncology, Hepatology, Health Sciences +9

Brain metastases treated with radiosurgery or hypofractionated stereotactic radiotherapy: outcomes and predictors of survival

Morena Sallabanda, M.I. García-Berrocal, Jesús Romero et al. · Clinical & Translational Oncology · 2020 · 12 citations

Neuro-oncology, Radiation Therapy, Brain Metastases +7